Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the “Inducement Grant”).
Related news for (RZLT)
- Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
- Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
- Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute, Inc. Announces Closing of Underwritten Offering